or Try an Advanced Search...

    Technical Analysis for COR - Cencora, Inc.

    Grade Last Price % Change Price Change
    B 243.20 0.92% 2.22
    COR closed up 0.92 percent on Wednesday, November 20, 2024, on 53 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Up Down
    Historical COR trend table...
    Date Alert Name Type % Chg
    NR7 Range Contraction 0.00%
    Inside Day Range Contraction 0.00%
    MACD Bearish Signal Line Cross Bearish 0.92%
    Inside Day Range Contraction 0.92%
    20 DMA Support Bullish 1.23%
    Golden Cross Bullish 1.23%
    Overbought Stochastic Strength 1.23%
    Overbought Stochastic Strength 0.14%
    Gapped Down Weakness 0.14%
    New 52 Week Closing High Bullish -2.49%
    Older End-of-Day Signals for COR ...

       Recent Intraday Alerts

    Alert Time
    Up 1% about 16 hours ago
    Possible NR7 about 18 hours ago
    Possible Inside Day about 18 hours ago
    60 Minute Opening Range Breakout about 18 hours ago
    Possible Inside Day 1 day ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    COR Chart by TradingView
    Basic chart:

    Profile

    Cencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around the world. We partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies. Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions. Our 46,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our responsibility to create healthier futures. Cencora is ranked #11 on the Fortune 500 and #24 on the Global Fortune 500 with more than $200 billion in annual revenue.
    Classification
    Sector: Healthcare
    Industry: Medical Distribution
    Keywords: S&P 500 Pharmaceutical Healthcare Products

    Is COR a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 13 McKesson Stock Gets A RS Rating Lift To 75
    Nov 13 McKesson, Cencora slapped with $266M in damages in Baltimore opioid lawsuit
    Nov 11 Cencora Full Year 2024 Earnings: EPS Misses Expectations
    Nov 9 Cencora's (NYSE:COR) Dividend Will Be Increased To $0.55
    Nov 8 Cardinal Health Stock Sees IBD RS Rating Improve To 71
    Nov 7 Cencora Reports Strong Revenue and EPS Growth in 2024
    Nov 7 Cencora to acquire Retina Consultants of America for $4.6B in cash
    Nov 6 Cencora, Inc. (COR) Q4 2024 Earnings Call Transcript
    Nov 6 Cencora to buy Retina Consultants of America for $4.6B
    Nov 6 Here's Why Cencora (COR) is a Strong Value Stock
    See more COR news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 250.9916
    52 Week Low 194.106
    Average Volume 1,475,074
    200-Day Moving Average 232.17
    50-Day Moving Average 232.48
    20-Day Moving Average 239.31
    10-Day Moving Average 245.14
    Average True Range 4.48
    RSI (14) 57.81
    ADX 23.72
    +DI 21.92
    -DI 20.11
    Chandelier Exit (Long, 3 ATRs) 237.56
    Chandelier Exit (Short, 3 ATRs) 240.87
    Upper Bollinger Bands 253.28
    Lower Bollinger Band 225.33
    Percent B (%b) 0.64
    BandWidth 11.68
    MACD Line 3.38
    MACD Signal Line 3.62
    MACD Histogram -0.2389
    Fundamentals Value
    Market Cap 48.85 Billion
    Num Shares 201 Million
    EPS 8.20
    Price-to-Earnings (P/E) Ratio 29.66
    Price-to-Sales 0.00
    Price-to-Book 0.00
    PEG Ratio 1.58
    Dividend 1.92
    Dividend Yield 0.79%
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 247.87
    Resistance 3 (R3) 247.49 245.57 247.09
    Resistance 2 (R2) 245.57 244.38 245.75 246.83
    Resistance 1 (R1) 244.38 243.64 244.98 244.76 246.57
    Pivot Point 242.46 242.46 242.75 242.64 242.46
    Support 1 (S1) 241.27 241.27 241.87 241.65 239.83
    Support 2 (S2) 239.35 240.53 239.53 239.57
    Support 3 (S3) 238.16 239.35 239.31
    Support 4 (S4) 238.54